公开(公告)号：US20240350515A1

公开(公告)日：2024-10-24

申请号：US18682824

申请日：2022-08-11

申请人： CHEMO RESEARCH, S.L.

发明人： Enrico COLLI ,  Salustiano PÉREZ

IPC分类号： A61K31/585 ,  A61K9/20

CPC分类号： A61K31/585 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054

摘要： The present invention relates to drospirenone for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea, comprising administering drospirenone in a biphasic regimen. The present invention furthermore relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, as well as to a pharmaceutical composition and a kit comprising drospirenone administered in such a biphasic regimen.

公开(公告)号：US12109218B2

公开(公告)日：2024-10-08

申请号：US17548755

申请日：2021-12-13

申请人： ARATANA THERAPEUTICS, INC.

发明人： Lesley Rausch-Derra ,  Tamara Newbold ,  Gopinath Devaraj ,  Akemi Shiraishi

IPC分类号： A61K31/64 ,  A61K9/00 ,  A61K9/20 ,  A61K31/437

CPC分类号： A61K31/64 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/437

摘要： The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

公开(公告)号：US12109214B2

公开(公告)日：2024-10-08

申请号：US17361995

申请日：2021-06-29

申请人： PRODRUGXTEND PTY LTD

发明人： Timothy Florin ,  Amirali Popat ,  Siddharth Jambhrunkar

IPC分类号： A61K31/52 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/28

CPC分类号： A61K31/52 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/08 ,  A61K9/20 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/28

摘要： The invention relates to pharmaceutical compositions comprising 6-thioguanine (6-TG) wherein the composition is formulated for release of 6-TG in the distal intestine. Methods for treating a disease or condition of the distal ileum that responds to 6-TG wherein the 6-TG is released in the distal intestine are also disclosed.

公开(公告)号：US12109196B2

公开(公告)日：2024-10-08

申请号：US18443689

申请日：2024-02-16

申请人： BioXcel Therapeutics, Inc.

发明人： Vasukumar Kakumanu ,  David Christian Hanley ,  Frank Yocca ,  Chetan Dalpatbhai Lathia ,  Lavanya Rajachandran ,  Robert Risinger

IPC分类号： A61K31/4174 ,  A61K9/00 ,  A61K9/06 ,  A61K9/20 ,  A61K9/70 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44 ,  A61P25/18 ,  A61P25/20 ,  A61P25/36

CPC分类号： A61K31/4174 ,  A61K9/006 ,  A61K9/06 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/7007 ,  A61K9/7015 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44 ,  A61P25/18 ,  A61P25/20 ,  A61P25/36

摘要： Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

公开(公告)号：US20240317768A1

公开(公告)日：2024-09-26

申请号：US18737044

申请日：2024-06-07

申请人： RAPT THERAPEUTICS, INC.

发明人： David J. Arnold ,  Omar Robles ,  Duane E. Rudisill ,  David J. Wustrow ,  Mikhail Zibinsky ,  Sami Karaborni

IPC分类号： C07D487/04 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  C07K16/28

CPC分类号： C07D487/04 ,  A61K9/0053 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/284 ,  C07K16/2818 ,  C07B2200/13

摘要： Crystalline forms of a C—C chemokine receptor type 4 (CCR4) antagonist, oral dosage forms of same and methods of using and preparing same, are provided.

公开(公告)号：US20240317687A1

公开(公告)日：2024-09-26

申请号：US18421849

申请日：2024-01-24

申请人： Cytokinetics, Inc.

发明人： Sheng CUI ,  Henry MORRISON ,  Karthik NAGAPUDI ,  Shawn D. WALKER ,  Charles BERNARD ,  Karl Bennett HANSEN ,  Neil Fred LANGILLE ,  Alan Martin ALLGEIER ,  Steven M. MENNEN ,  Jacqueline C.S. WOO ,  Bradley Paul MORGAN ,  Alex MUCI (Deceased)

IPC分类号： C07D213/75 ,  A61K9/20 ,  A61K31/496 ,  A61K47/38

CPC分类号： C07D213/75 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/496 ,  A61K47/38

摘要： Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US20240315974A1

公开(公告)日：2024-09-26

申请号：US18736621

申请日：2024-06-07

申请人： MATRIPHARM INTERNATIONAL INC.

发明人： Tien Canh LE ,  Mircea-Alexandru MATEESCU

IPC分类号： A61K9/20 ,  A61K31/192 ,  A61K31/405 ,  A61K31/616 ,  A61K45/06

CPC分类号： A61K9/2059 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/205 ,  A61K9/2054 ,  A61K31/192 ,  A61K31/405 ,  A61K31/616 ,  A61K45/06

摘要： The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.

公开(公告)号：US20240307311A1

公开(公告)日：2024-09-19

申请号：US18577095

申请日：2022-07-07

申请人： ROQUETTE FRERES

发明人： Yuan-Siang LUI ,  Keat-Theng CHOW ,  Rajeev GOKHALE ,  Olaf HAEUSLER

IPC分类号： A61K9/20 ,  A61K31/496 ,  A61K31/522 ,  B33Y70/00 ,  C08B31/04 ,  C08B31/12

CPC分类号： A61K9/2059 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2095 ,  A61K31/496 ,  A61K31/522 ,  B33Y70/00 ,  C08B31/04 ,  C08B31/12

摘要： The instant invention relates to a printable material for 3D printing comprising a hydrolyzed and functionalized starch compound. It also relates to a process for 3D printing using the same. It also relates to products, in particular solid dosage forms, obtained thereof by 3D printing.

公开(公告)号：US20240300950A1

公开(公告)日：2024-09-12

申请号：US18427226

申请日：2024-01-30

申请人： BIOMEA FUSION, INC.

发明人： Satish Goud Puppali ,  James T. Palmer ,  Thorsten A. Kirschberg ,  Angelina Sau Man Wong ,  Heow Meng Tan ,  Jay Li ,  Ming Lin ,  Ming Gao ,  Junlu Ding ,  Shuang Li ,  Yuyao GU ,  Hongyan He ,  Bo Zheng ,  Yanjing Zhou ,  Mei You ,  Yihong Qiu

IPC分类号： C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  A61K31/5377 ,  A61K45/06 ,  A61P3/10 ,  A61P35/02

CPC分类号： C07D487/04 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2059 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/5377 ,  A61K45/06 ,  A61P3/10 ,  A61P35/02

摘要： Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I),




including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.

公开(公告)号：US12077502B2

公开(公告)日：2024-09-03

申请号：US17871065

申请日：2022-07-22

申请人： PRAXIS PRECISION MEDICINES, INC.

发明人： Kiran Reddy ,  Margaret S. Lee ,  Gabriel Maurice Belfort ,  Sapna Makhija Garad ,  Mahesh Padval ,  Randall Wagner ,  Marion Wittmann

IPC分类号： C07D211/34 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K31/445 ,  A61K47/38 ,  A61P25/14 ,  C07D211/26

CPC分类号： C07D211/34 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/445 ,  A61K47/38 ,  A61P25/14 ,  C07D211/26 ,  C07B2200/13

摘要： Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.